Adebrelimab and Chemoradiotherapy in High-risk LANPC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorSun Yat-sen University
About this trial
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
Eligibility criteria
Qualifiers
Patients with histologically confirmed nasopharyngeal carcinoma.
Tumor staged as IVA+T3N2M0 (AJCC 8th).
Eastern Cooperative Oncology Group performance status ≤1.
Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L.
Disqualifiers
Age > 65 or < 18.
Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA >1×10e3 copies/ml or 200IU/ml
Hepatitis C virus (HCV) antibody positive
Has active autoimmune disease, except type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia).
Trial design
Treatments tested in this trial
- Adebrelimab
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Sun Yat-sen University
Lead sponsor
Nanfang Hospital, Southern Medical University
Collaborator
West China Hospital
Collaborator
The First Affiliated Hospital of Xiamen University
Collaborator
Source ClinicalTrials.gov